Abbott Laboratories (ABT) - NYSE
  • Fri, Jul. 15, 12:25 PM
    • In a statement, point-of-care diagnostics firm Alere (ALR +7.6%) confirms that will restate its annual financial statements for 2013, 2014 and 2015 and interim statements for the periods ended March 31, 2015 and September 30, 2015 after identifying the specific revenue recognition issues that have delayed the filing of its 2015 reports.
    • The specific areas pertaining to the timing of revenue recognition were mainly confined to Africa, where revenue was recorded when product was shipped to the distributor but the title did not transfer until the distributor paid for the products in full or the distributor was not obligated to pay the bill until the products were sold to end users.
    • Another problem was "bill and hold" transactions (an invoice is generated but the product remains in inventory), principally in China (any legitimate accounting firm will consider this a significant "no-no").
    • There were other unspecified transactions where Alere recognized revenue prior to satisfying all the contractual criteria for the transfer of title and risk to the customer.
    • The company says the revisions will not be material since they do not impact the total amount of recorded revenue other than the change brought about by establishing a returns allowance for its Indian subsidiary. It plans to file its 2015 financials as soon as feasible, followed by its Q1 2016 10-Q. It admits that it expects to report one or more material weaknesses in its disclosure controls and procedures and internal control over financial reporting.
    • On a preliminary basis, revenue ($M) for 2015 and Q1 2016 will be $2,447 - 2477 and $573 - 593, respectively. Net income will be $10 - 25 and $(8) - 2, respectively, and non-GAAP EBITDA $505 - 520 and $106 - 116.
    • Analysts expect the $5.8B takeover by Abbott Laboratories (ABT -0.4%) to proceed.
    | Fri, Jul. 15, 12:25 PM | 5 Comments
  • Wed, Jul. 13, 5:12 AM
    • The FTC has requested additional information from Abbott Laboratories (NYSE:ABT) and St. Jude Medical (NYSE:STJ), which are attempting to complete a $25B deal combining two of the leading makers of heart-related devices.
    • The request extends the waiting period - the time frame before companies can close a transaction - by 30 days.
    | Wed, Jul. 13, 5:12 AM | 1 Comment
  • Thu, Apr. 28, 6:56 AM
    • Hot off the press: Abbott Labs (NYSE:ABT) acquires St. Jude Medical (NYSE:STJ) for $25B. Developing...
    • Update: Under the terms of the deal, St. Jude shareholders will receive $46.75 in cash and 0.8708 of a share of Abbott common stock representing a total per-share value of $85. Abbott intends to fund the cash portion with medium- and long-term debt.
    • The deal will be accretive to Abbott's non-GAAP EPS in the first year post close, adding $0.21 in 2017 and $0.29 in 2018. Anticipated pre-tax synergies should be $500M by 2020.
    • The combined annual sales of the Abbott's cardiovascular business and St. Jude is ~$8.7B, with #1 or #2 market positions across almost every area in cardiovascular devices.
    • Separately, Abbott plans to issue $3B of common stock in the secondary market to rebalance its capital structure. Timing has yet to be determined.
    • Abbott will host a conference call this morning at 8:00 am ET to discuss the transaction.
    • In premarket trading, ABT is down 5% and STJ is up 27%, both on robust volume.
    | Thu, Apr. 28, 6:56 AM | 29 Comments
  • Mon, Feb. 1, 8:07 AM
    • Abbott Laboratories (NYSE:ABT) acquires point-of-care diagnostics firm Alere (NYSE:ALR) for $56 per share ($5.8B). The deal will be immediately accretive to earnings and is expected to add $0.12 - 0.13 to EPS in 2017 and more than $.20 in 2018. Annual pre-tax synergies should be ~$500M by 2019.
    • Under the terms of the deal, Alere shareholders will receive $56 per share in cash. Abbott will also assume $2.6B in Alere outstanding debt.
    • Waltham-MA-based Alere generates ~$2.5B in sales per year. Shares are up 46% premarket on light volume.
    | Mon, Feb. 1, 8:07 AM | 17 Comments
  • Aug. 27, 2015, 9:05 AM
    • Abbott Laboratories (NYSE:ABT) has denied a report that it's preparing an offer for St. Jude Medical (NYSE:STJ) that would value the medical device maker at about $25B.
    • St. Jude shares have now pared back their gains in early trading after surging 17% on the rumor.
    • STJ +4.9% premarket
    • Previously: FT: Abbott prepping $25B takeover offer for St. Jude (Aug. 27 2015)
    | Aug. 27, 2015, 9:05 AM
  • Aug. 27, 2015, 7:18 AM
    • Abbott Laboratories (NYSE:ABT) is preparing a takeover bid for St. Jude Medical (NYSE:STJ) that is likely to value the medical device maker at $25B, FT reports.
    • Sources say the firm has been working with advisers for several weeks, lining up the financing for a cash and stock offer.
    • Abbott and St. Jude already have a strong alliance in the field of cardiovascular devices, and a full merger would give the enlarged company greater leverage in negotiating with healthcare providers.
    • STJ +13.2% premarket
    • Update: Quoting a spokesperson, Bloomberg says Abbott isn't making an offer for St. Jude.
    | Aug. 27, 2015, 7:18 AM
  • Jul. 30, 2015, 11:42 AM
    • Abbott Laboratories (ABT -0.6%) acquires privately-held Roseville, MN-based Tendyne Holdings for $250M plus regulatory-based milestones. Abbott will pay $225M upfront to acquire the equity in Tendyne that it does not already own.
    • Tendyne is developing a replacement tissue valve for the treatment of advanced mitral regurgitation that can be placed into the heart without the use of cardio-pulmonary bypass.
    | Jul. 30, 2015, 11:42 AM | 1 Comment
  • Apr. 22, 2015, 3:33 PM
    • According to Bloomberg, Omnicare (OCR +7.4%) is reportedly working with financial advisors seeking a buyer. Company representatives have declined to comment. Trading halted.
    • Consensus Q1 view is EPS of $1.01 on revenues of $1.6B.
    • The company is currently embroiled in a lawsuit filed by the U.S. Department of Justice over alleged kickbacks from Abbott Labs (ABT +2.4%) in exchange for purchasing the dementia drug Depakote.
    • Previously: DOJ sues Omnicare over alleged dementia drug kickbacks (Dec. 22, 2014)
    | Apr. 22, 2015, 3:33 PM | 1 Comment
  • Jan. 28, 2015, 12:38 PM
    • The European Commission clears Mylan's (MYL -0.1%) $5.3B acquisition of Abbott's (ABT +0.7%) non-U.S. Developed Markets Specialty and Branded Generics Business. The EC is concerned that the transaction would potentially reduce competition so its approval is contingent upon the divestment of some of Mylan's businesses in Germany, the U.K., France, Ireland and Italy.
    | Jan. 28, 2015, 12:38 PM
  • Dec. 12, 2014, 12:22 PM
    • Abbott Laboratories (ABT -0.7%) finalizes its takeout of Russian pharmaceutical firm Veropharm. It acquired control of the company via its purchase of the holding company, Limited Liability Company Garden Hills, that owned ~98% of Veropharm, for 16.7B rubles (~$305M).
    • Previously: Abbott to buy Russian pharma company (June 23, 2014)
    | Dec. 12, 2014, 12:22 PM | 3 Comments
  • Nov. 17, 2014, 9:16 AM
    • Zoetis (NYSE:ZTS) acquires Abbott (NYSE:ABT) division Abbott Animal Health, a companion animal health business focused on the veterinary surgical suite, for $255M.
    • The transaction should close in Q1 2015.
    | Nov. 17, 2014, 9:16 AM
  • Oct. 22, 2014, 12:24 PM
    • In response to the changes in the tax code related to inversions, Abbott (ABT -1.1%) and Mylan (MYL -2.5%) adjust the terms of their $5.3B all-stock deal. The pricing terms related to product manufacturing and supply have been changed in favor of New Mylan and the number of shares of stock to be issued to Abbott have been increased to 110M from 105M.
    • Former shareholders of Mylan will own ~78% of New Mylan and Abbott and its affiliates will own ~22%. The transaction is expected to close in Q1 2015.
    | Oct. 22, 2014, 12:24 PM
  • Jul. 14, 2014, 7:03 AM
    • Mylan (NASDAQ:MYL) acquires Abbott Labs' (NYSE:ABT) ex-U.S. specialty and branded generics business for $5.3B in an all-stock transaction. Abbott will receive 105M shares of MYL common stock representing a 21% ownership stake.
    • The assets include a portfolio of more than 100 drugs that generate ~$1.9B in annual sales. The deal includes a sales force of ~2,000 representatives in more than 40 non-U.S. markets and two manufacturing facilities. The transaction will be immediately accretive to Mylan adding ~$0.25/share to diluted EPS the first year and increasing thereafter.
    | Jul. 14, 2014, 7:03 AM | 1 Comment
  • Jul. 11, 2014, 7:48 PM
    • Reuters reports that generic drug firm Mylan (MYL -1%) is in advanced negotiations with Abbott Laboratories (ABT +0.1%) to purchase a multibillion dollar portfolio of its established off-patent Europe-based drugs. The transaction is a tax inversion deal that will enable Mylan to redomicile in Switzerland.
    • Mylan has been in the hunt for foreign assets since its failed attempt to buy Swedish drugmaker Meda AB earlier this year. Its two main competitors, (TEVA +0.9%) and Actavis (ACT +0.5%) are domiciled in lower tax countries.
    • Abbott will use the proceeds of the sale, rumored to be as high as $5B, to invest in higher growth opportunities.
    | Jul. 11, 2014, 7:48 PM | 3 Comments
  • Jun. 23, 2014, 4:14 PM
    • Abbott Labs (ABT -0.3%) signs an agreement to acquire Russian pharmaceutical manufacturer Veropharm via purchasing Limited Liability Company Garden Hills, a holding company that owns a controlling interest in Veropharm. The purchase price range is 13.6B - 17B rubles (US$395M - 495M) depending on the size of Garden Hills' stake at the time of closing. Abbott will also assume net debt of 4.7B rubles (US$136M). The transaction will be funded with cash on the balance sheet and will close in Q4.
    • The acquisition establishes a manufacturing presence for Abbott in Russia and enables it to obtain a portfolio of products in women's health, CNS, cardiovascular, gastroenterology and oncology.
    | Jun. 23, 2014, 4:14 PM | 1 Comment
  • May 16, 2014, 7:54 AM
    • Abbott Labs (ABT) doubles its Latin American presence with its purchase of Chilean generic drug firm CFR Pharma for $2.9B cash plus assumption of $430M in debt.
    • The acquisition will add $900M to Abbott's top line in 2015 and double-digit sales growth over the next few years.
    • CFR markets over 1,000 products. It employs 7,000 people and has R&D and manufacturing facilities in Chile, Colombia, Peru and Argentina.
    • The Latin American pharmaceutical market is valued at $73B and is forecasted to grow to $124B in four years.
    | May 16, 2014, 7:54 AM | 6 Comments
Company Description
Abbott Laboratories engages in the discovery, development, manufacture and sale of a broad and diversified line of health care products. The company operates through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products.... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States